Is Perspective Therapeutics, Inc. (CATX) a Buy, Sell, or Hold?
AMEX : CATX
Perspective Therapeutics, Inc.
$3 USD
$0.03 (1.01%)
- Volume
- 939.5K
- Average Volume
- 1.75M
- Market Capitalization
- $342.14M
- P/E Ratio
- -0.11
- Dividend Yield
- 0.00%
- Price Target
- $14.00
- Year High
- $6.16
- Year Low
- $1.96
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.75
Company Overview
AMEX
Johan Spoor
Medical - Devices
Healthcare
CATX
165
US
USD
Liquidity Metrics
0.01
8.75
8.75
1.71
0.00
Sales & Valuation
-$
553.62
0.01
-3.19
-103.59
Profitability
-$1.4
-$103.12M
-17982.69%
-18194.17%
-41.84%
-27.05%
P/E Metrics
-0.11
0.00
0.00
Analyst Price Target & Rating
$14.00
$16.00
$12.00
3/5
11 Analysts
-78.57%
Financial Health Scores
0.74
3/9
$243.87M
$410.77M
$63.33M
-$114.28M
Key Metrics (TTM)
$292.4M
473.13
-2.64
8.75
-41.84%
-31.33%
-3575.57%
-31.37%
-3636 days
Company Executives
| Name | Title |
|---|---|
| Joel David Sendek | CFO & Principal Financial Officer |
| Johan Spoor | Chief Executive Officer & Director |
| Jonathan R. Hunt | Chief Accounting Officer |
| Shane Cobb | Executive Vice President of Operations |
| Annie J. Cheng | Vice President of Investor Relations |
| Markus Puhlmann | Chief Medical Officer |
| Paul Lyne | Chief Science Officer |
| Michael K. Schultz | Co-Founder & Senior Scientific Advisor |
| Amos Hedt PGradDip | Chief Business Strategy Officer |
| Andrew Bright | Executive Vice President of Brachytherapy |
| Chris Nenno | General Counsel & Corporate Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Perspective Therapeutics, Inc. (AMEX:CATX) Stock
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. Th ... e entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
2026-08-04 10:41:27
Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
2026-08-03 11:35:25
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
Perspective Therapeutics, Inc. $CATX Shares Bought by Avidity Partners Management LP
2026-08-01 03:44:02
Avidity Partners Management LP grew its stake in shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 88.4% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,049,999 shares of the company's stock after purchasing an additional 2,839,266 shares during the quarter.
2026-07-31 06:30:00
SEATTLE, July 31, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its second quarter 2026 financial results and provide a business update on Monday, August 10, 2026 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
2026-07-29 10:56:12
After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics (CATX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Ally Bridge Group NY LLC Makes New Investment in Perspective Therapeutics, Inc. $CATX
2026-07-29 03:45:46
Ally Bridge Group NY LLC acquired a new position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 926,557 shares of the company's stock, valued at approximately $3,864,000. Perspective Therapeutics comprises 3.1% of Ally
ADAR1 Capital Management LLC Purchases 654,142 Shares of Perspective Therapeutics, Inc. $CATX
2026-07-29 03:45:35
ADAR1 Capital Management LLC boosted its position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) by 687.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 749,335 shares of the company's stock after buying an additional 654,142 shares
2026-07-28 06:30:00
SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the European Commission (EC) has granted orphan medicinal product designation for [²¹²Pb]VMT-α-NET for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).
Frequently Asked Questions
-
What is the current Perspective Therapeutics, Inc. (CATX) stock price?
-
Perspective Therapeutics, Inc.(AMEX:CATX) stock price is $3 in the last trading session. During the trading session, CATX stock reached the peak price of $6.16 while $1.96 was the lowest point it dropped to. The percentage change in CATX stock occurred in the recent session was 1.01% while the dollar amount for the price change in CATX stock was $0.03.
-
CATX's industry and sector of operation?
-
The AMEX listed CATX is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of CATX?
-
Joel David Sendek | CFO & Principal Financial Officer
Johan Spoor | Chief Executive Officer & Director
Jonathan R. Hunt | Chief Accounting Officer
Shane Cobb | Executive Vice President of Operations
Annie J. Cheng | Vice President of Investor Relations -
How many employees does CATX have?
-
Number of CATX employees currently stands at 165. CATX operates from 2401 Elliott Avenue, Seattle, WA 98121, US.
-
Link for CATX official website?
-
Official Website of CATX is: https://www.perspectivetherapeutics.com
-
How do I contact CATX?
-
CATX could be contacted at phone #509 375 1202 and can also be accessed through its website. CATX operates from 2401 Elliott Avenue, Seattle, WA 98121, US.
-
How many shares of CATX are traded daily?
-
The average number of CATX shares traded daily for last 3 months was 1.75M.
-
What is the market cap of CATX currently?
-
The market value of CATX currently stands at $342.14M with its latest stock price at $3